You can bet at least a few pols will have Pfizer in their sights.

In the midst of plans to lower its U.S. tax liability by merging with a foreign company, the drug giant announced it will be raising prices for over 100 of its products, some by as much as 20 percent.

Reuters reports big price hikes for a number of high-profile drugs, based on a report by Wolters Kluwer, an international consulting firm.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Employer-Paid